1. Introduction {#s0005}
===============

Radiotherapy is used in the treatment of up to 50% of cancer patients and around 40% of long-term cancer survivors underwent radiotherapy at some point in their treatment. For example, approximately half of the 1.1 million men diagnosed with prostate cancer worldwide each year receive radiotherapy, and the 5-year relative survival rates approach 100% for non-metastatic disease ([@bb0155]). Although modern treatments minimize radiation doses to surrounding normal tissues, some men develop long-term toxicity ([@bb0030]). The risk of severe toxicity limits doses, which aim to keep the prevalence below 5%. Mild and moderate effects are common (10--50% of those treated) ([@bb0005], [@bb0075], [@bb0135], [@bb0190], [@bb0235], [@bb0285]), impact negatively on quality-of-life, and are an important factor when men consider treatment options ([@bb0070]).

There is a need for a test that reflects a cancer patient\'s radiosensitivity and predicts the likelihood of toxicity. Many assays have been explored but none proved sufficiently reliable for clinical application. Over the past 15 years interest increased in identifying the genetic variants associated with risk of toxicity. The rationale behind the work is that a future test based on a germline polygenic risk score will not suffer from the poor reproducibility associated with other assays measuring radiosensitivity ([@bb9005]).

Mutations associated with well-characterized radiosensitivity syndromes such as ataxia telangiectasia ([@bb0295]) are rare and do not explain the general inter-individual variation in toxicity following radiotherapy ([@bb0245]). Rather, it is hypothesized that common genetic variants, such as single nucleotide polymorphisms (SNPs) account for most of the heritability of radiosensitivity ([@bb0315]). Studies have begun to identify common variants associated with radiotherapy toxicity. Candidate gene studies showed rs2868371 in *HSPB1* (MIM [602195](602195){#ir0005}) ([@bb0200], [@bb0220]) and rs1800469 in *TGFB1* (MIM [190180](190180){#ir0010}) ([@bb0130]) are associated with late effects of lung radiotherapy; and rs1800629 in *TNF* (MIM [191160](191160){#ir0015}) ([@bb0290]) and rs1139793 in *TXNRD2* (MIM [606448](606448){#ir0020}) ([@bb0085]) are risk SNPs for late toxicity following breast radiotherapy. Genome-wide association studies (GWAS) identified a locus on chr11q14.3 associated with rectal bleeding ([@bb0175]) and a locus on chr2q24.1 within *TANC1* (MIM [611397](611397){#ir0025}) associated with overall toxicity ([@bb0110]) following radiotherapy for prostate cancer. Another study showed more associations at the p-value \< 5 × 10^− 7^ level than expected by chance, providing the strongest evidence to date that many common genetic variants are associated with risk of toxicity ([@bb0020]).

Recently published GWAS have limitations that we aimed to overcome by using a meta-analysis approach. The published studies used a multi-stage approach, where a small first-stage cohort was analyzed for a genome-wide panel of SNPs and only the most significant SNPs were genotyped in validation datasets. Thus, true positive SNPs were likely missed because they were not tested in the full set of individuals. Here, the Radiogenomics Consortium ([@bb0320]) undertook a meta-analysis of four GWAS in order to maximize statistical power ([@bb0050]) to discover additional risk variants. It is known that risk factors for late toxicity include not only genetics but also dosimetric parameters, co-morbidities, and patient demographics ([@bb9000]). The latter factors can vary between cohorts as can the treatment (e.g. in prostate cancer: external beam or brachytherapy; type of fractionation -- large or small doses per fraction; variable use of hormone therapy; variable use of surgery) and scales used to assess toxicity. There were concerns, therefore, whether the heterogeneity across cohorts might limit our ability to identify variants.

This study is important because our ability to identify enough SNPs for a risk profile for clinical implementation is dependent on combining multiple heterogeneous cohorts. The aim was to show that multi-center radiotherapy cohorts could be harmonized and analyzed to identify risk SNPs by increasing the number of individuals analyzed in a single stage ([@bb0260]). STROGAR guidelines ([@bb0185]) for reporting radiogenomic studies, which build on the STREGA and STROBE guidelines ([@bb0195], [@bb0310]), were followed throughout.

2. Subjects & Methods {#s0010}
=====================

2.1. Participants {#s0015}
-----------------

The four cohorts (RAPPER, RADIOGEN, Gene-PARE, and CCI) comprised individuals with adenocarcinoma of the prostate treated with radiotherapy with curative intent. [Table 1](#t0005){ref-type="table"} shows the number of individuals in each cohort the number with genome-wide SNP data available, and the final number included in the GWAS meta-analysis after excluding samples for quality control or due to missing data. Informed consent was obtained from all study participants and all studies conform to standards indicated by the Declaration of Helsinki.

RAPPER (UKCRN1471; n = 727) ([@bb0035]) was approved by the Cambridge South Research Ethics Committee (05/Q0108/365). Individuals received neoadjuvant androgen suppression and external beam radiotherapy, (EBRT): 233 from MRC RT01 (ISRCTN47772397) ([@bb0280]) and 494 from CHHiP (ISRCTN97182923) ([@bb0075]).

RADIOGEN (n = 741) was approved by the Galician Ethical Committee. Individuals received conformal radical or post-prostatectomy EBRT at the Clinical University Hospital of Santiago de Compostela, Spain ([@bb0105]), and 511 individuals had hormone therapy.

Gene-PARE (n = 895) ([@bb0145]) was approved by the Mount Sinai Medical Center Institutional Review Board. Individuals had brachytherapy with/without EBRT at the Mount Sinai Hospital, New York, and 472 received hormone therapy. ^125^I (160Gy; TG-43) was used in those undergoing brachytherapy alone and ^103^Pd (124Gy) in those also receiving EBRT ([@bb0265], [@bb0275]).

The CCI cohort (n = 155) ([@bb0175]) was approved by the Health Research Ethics Board of Alberta (Cancer). Individuals were recruited from the Cross Cancer Institute in Edmonton and the Tom Baker Cancer Centre in Calgary, Alberta, Canada. All 155 individuals underwent EBRT and 82 received hormonal therapy.

Total biologic effective dose (BED) ([@bb0270]) was calculated for individuals in all four studies to compare radiation exposure across studies (α/β = 3).

2.2. Assessment of Late Radiotherapy Toxicity {#s0020}
---------------------------------------------

Participants were assessed prospectively for toxicity (see Table S1). Toxicity was measured 1.5--2.5 years following treatment with the latest value used if more than one assessment was recorded during this follow-up window. For rectal bleeding in Gene-PARE, a 1--5 year window was allowed, because the scoring system assigns grades based on whether rectal bleeding occurs as a single incident or intermittent symptoms over time. Urinary endpoints were re-graded to harmonize across the studies (Table S2). As urinary daytime frequency and nocturia were recorded separately (RAPPER, Gene-PARE) or as a single endpoint (RADIOGEN, CCI), they were collapsed into a single endpoint in RAPPER and Gene-PARE by taking the maximum score between the two.

Changes in scores from baseline were calculated for each endpoint. Improvement from baseline (i.e. a negative change in score) was coded as 0. Table S3 lists the two-year prevalence of the toxicity endpoints in the four cohorts, including samples that were not genotyped. A Standardized Total Average Toxicity (STAT) score was calculated as described previously ([@bb0015]) to provide an overall measure of toxicity. All samples with 2-year toxicity data available and the endpoints described in Table S1 were used to calculate STAT.

Data simulation determined the most statistically powerful way to analyze toxicity: ordinal logistic regression of exact change in toxicity grade from baseline; binary logistic regression with no change in toxicity grade compared with a ≥ 1 point increase in toxicity grade; or binary logistic regression with change in toxicity grade ≤ 1 point compared with a ≥ 2 point change. Genotype and toxicity phenotype data for 600 individuals were simulated under two models: (1) null (no association), and (2) alternative model of linear association characterized by a log-linear per-allele increase in odds of toxicity. Under both types of model, genotypes were randomly assigned to each subject according to one of five minor allele frequencies (MAF): 0.05, 0.15, 0.25, 0.35 or 0.45. To create the null data set, a toxicity grade was also randomly assigned to each subject. Datasets representing a log-linear association between genotype and toxicity were created by assigning each subject a toxicity risk score that was calculated using their genotype and a pre-specified effect size (log(odds ratio) = log(1.5)):$$R_{i} = \left( {\text{genotype}_{i} \times \beta} \right) - \left( {2 \times {MAF} \times \beta} \right)$$

for subjects i = 1 ... n;

β the pre-specified effect size;

(2 × MAF × β) the population average.

A random risk was also added to each score, representing non-genetic factors that may influence toxicity, to create a logistic distribution of toxicity risk. This logistic distribution was then used to assign a toxicity grade to each subject such that subjects lying at the high end of the risk distribution had higher toxicity grades than those at the low end of the distribution. Under both types of model, two phenotype distributions were simulated to reflect the distributions of urinary frequency and rectal bleeding observed in RAPPER.

Each simulation was repeated 100,000 times. Three regression models were fitted to each set of simulated data, with toxicity grade as the outcome variable and genotype as the independent variable. Each model produced a p-value for comparison.

The power of each type of model applied to the log-linear association data was assessed by tabulating the number of p-values (out of 100,000) achieving statistical significance. Applying a simple Bonferroni correction to the observed p-values to account for 100,000 test repeats, a test was considered statistically significant if p-value \< 5 × 10^− 6^. The model that detected the most significant associations was deemed most powerful. p-Values obtained from analyses of the null data sets were assessed for type I error.

Results from 100,000 simulations showed that both ordinal logistic and binary (no versus ≥ 1 point change) logistic regression were equally powerful statistical approaches (Table S4), and binary logistic regression (no change in toxicity grade compared with a ≥ 1 point increase in toxicity grade) was used for the primary analysis. No model displayed higher-than-expected type I errors. Data simulation was performed using R ([@bb0230]) with the Ordinal package ([@bb0045]).

2.3. Genotyping, Quality Control and Imputation {#s0025}
-----------------------------------------------

Germline DNA was genotyped using commercial SNP arrays as part of previously completed GWAS ([@bb0020], [@bb0110], [@bb0170], [@bb0175], [@bb0180]). Quality control filtering removed SNPs that were missing in \> 2.5% of samples, had MAF \< 1% or displayed frequencies deviating from those expected under Hardy-Weinberg Equilibrium (p-value \< 10^− 6^). Samples with \> 5% of SNPs missing, showing cryptic relatedness, showing excess heterozygosity or being principle component analysis (PCA) outliers were removed ([Table 1](#t0005){ref-type="table"}). After filtering, the four datasets had genotyping rates \> 99%. To minimize potential confounding by population structure, individuals with non-European ancestry ([Table 1](#t0005){ref-type="table"}) were excluded using PCA performed with samples of known ancestry from the International HapMap Project ([@bb0160]).

Imputation using IMPUTE2 software ([@bb0150]) with the 1000 Genomes phase I, version 3 (release date 3/16/2012) reference panel (1092 individuals from all 14 populations) ([@bb0120]) yielded \~ 38 million SNPs, small insertions and deletions, and structural variants in each study. These datasets were filtered as above in addition to removing SNPs with information score, a measure of imputation certainty, \< 0.3. The final datasets included in the GWAS meta-analysis were: 6,672,177 SNPs in 527 RAPPER participants; 6,767,156 SNPs in 597 RADIOGEN participants; 6,627,946 SNPs in 290 Gene-PARE participants; and 6,504,337 SNPs in 150 CCI participants.

SNP rs17599026 was directly genotyped in the RADIOGEN and RAPPER samples using a TaqMan assay (forward primer sequence TGCTCATGATGAAGGTATGCTTTCT, reverse primer sequence ACAAAACTGTATTCCCAAGACAAAGC and probe sequences CACCATCCTAAAGCAGTG plus ACCATCCTAAAACAGTG; Applied Biosystems, Thermo Fisher Scientific) according to the manufacturer\'s standard protocol (PCR annealing and extension performed at 60 °C for 1 min × 40 cycles). It was not possible to design a TaqMan assay with high specificity for rs7720298 as it is immediately adjacent to another SNP (rs7720176).

2.4. Statistical Analysis {#s0030}
-------------------------

Individual GWAS were analyzed using binary logistic (individual toxicity endpoints) or linear (STAT) regression, adjusting for non-genetic risk factors identified by QUANTEC ([@bb0215], [@bb0305]). These were: age at treatment, diabetes, rectal volume and BED in analysis of rectal bleeding; age at treatment, transurethral resection of the prostate (TURP) prior to radiotherapy, baseline symptom grade and BED in analysis of urinary endpoints; and all factors in analysis of STAT. Hormone therapy was also included in the Gene-PARE and CCI analyses because baseline symptoms were assessed prior to completion of hormone therapy. Multivariable regression was performed using SNPTEST software ([@bb0205]) with the frequentist test and expected method. The expected method uses the genotype dosages produced from imputation, which account for the uncertainty in using imputed genotypes rather than experimentally determined genotypes. Thus, inaccuracy related to using imputed data was accounted for in the statistical analysis. An additive genetic inheritance model was assumed in all analyses.

A fixed-effects meta-analysis with inverse variance weighting was performed using the regression beta coefficients and standard errors produced by SNPTEST. Studies have shown fixed-effects to be more statistically powerful compared with random-effects when the primary purpose is SNP discovery rather than refinement of the effects size estimate ([@bb0100]). A chi-squared test of heterogeneity was performed for each SNP. SNPs considered significant had a meta-p-value ≤ 5 × 10^− 8^ and agreement in effect direction across all cohorts. Significant SNPs were re-analyzed using an ordinal logistic regression model.

Regions of linkage disequilibrium were defined based on r^2^ ≥ 0.5 in SNPs from the 1000 Genomes European population with the meta-analysis top hits using Haploview software ([@bb0025]). The most recent release of the 1000 Genomes data (version 5, release date 5/2/2013) was used to estimate linkage disequilibrium.

2.5. Power Calculations {#s0035}
-----------------------

Power calculations were performed using the web-based Genetic Power Calculator ([@bb0225]) assuming a sample size of 1564 individuals, a phenotype prevalence of 20%, and type I error of 5 × 10^− 8^.

3. Results {#s0040}
==========

[Table 2](#t0010){ref-type="table"} summarizes the cohort characteristics and [Table 3](#t0015){ref-type="table"} the toxicity prevalences of the 1564 men treated for prostate cancer who were included in the analysis. Two years following radiotherapy 17.8% (277 of 1557) of individuals experienced rectal bleeding, 15.0% (212 of 1410) an increase in urinary frequency, and 8.1% (101 of 1245) a decrease in urine stream. The meta-analysis had ≥ 99% power to detect SNPs with MAF ≥ 10% and per-allele effect size ≥ 2 assuming a genome-wide significance threshold of 5 × 10^− 8^ ([Table 4](#t0020){ref-type="table"}).

Meta-analysis Q-Q plots (Fig. S1) show no genomic inflation, suggesting that population structure was adequately controlled using principal components analysis to exclude outliers with non-European ancestry. The most statistically significant SNPs associated with late toxicity are listed in [Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}, which show several SNPs had meta-p-values reaching or approaching significance (p-value ≤ 5 × 10^− 6^) with concordant effect direction across the individual studies. Three SNPs reached genome-wide significance: rs17599026 on 5q31.2 with urinary frequency (3.12, 95% CI 2.08--4.69, p-value 4.16 × 10^− 8^); rs7720298 on 5p15.2 with decreased urine stream (OR 2.71, 95% CI 1.90--3.86, p-value = 3.21 × 10^− 8^); and rs11230328 on 11q12.2 with STAT score (Beta 0.31, 95% CI 0.21--0.41, p-value = 6.27 × 10^− 10^). rs17599026 was directly genotyped in the GenePARE and CCI studies and imputed in the RADIOGEN (information score = 0.90) and RAPPER (information score = 0.87) studies. rs7720298 was imputed in all four studies (RADIOGEN information score = 0.91, RAPPER information score = 0.93, GenePARE information score = 0.94, and CCI information score = 0.95) and rs11230328 was imputed in all four studies (RADIOGEN information score = 0.68, RAPPER information score = 0.61, GenePARE information score = 0.88, and CCI information score = 0.97). To provide a more interpretable effect size for rs11230328, STAT score was dichotomized at the mean and analyzed using logistic regression, which resulted in an OR of 1.59 (95% CI 1.25--2.02). There were no genome-wide significant SNPs associated with rectal bleeding, and though several approached significance, these require investigation in future larger studies. [Fig. 1](#f0005){ref-type="fig"} shows forest plots for the SNPs that reached the genome-wide significance threshold.

In order to confirm the quality of the imputation, rs17599026 was genotyped directly in the RADIOGEN and RAPPER samples. Genotyping was successful in 645 of 654 RADIOGEN samples (correlation between the imputed and genotyped data of 0.88) and 595 of 600 RAPPER samples (correlation between the imputed and genotyped data of 0.85). These results confirmed that the genotypes are in strong agreement with the imputed data. When the direct genotype data was used in analysis, rs17599026 showed an association signal consistent with that seen using the imputed data, though the p-value fell short of the strict threshold for genome-wide significance (OR 2.48, 95% CI 1.68--3.63, p-value = 3.66 × 10^− 6^).

Associations between the top SNPs (meta-analysis p-value ≤ 5 × 10^− 6^) and toxicity severity were modeled using ordinal logistic regression ([Table 9](#t0045){ref-type="table"}). For all SNPs, the p-value from ordinal logistic regression was similar to that from binary logistic regression. For several SNPs the association signal improved slightly with the ordinal logistic model: rs12497518, rs141044160, rs6999859, and rs4804134 associated with rectal bleeding; rs17599026, rs7366282, rs4534636, rs10101158, rs10209697, rs6003982, and rs7356945 associated with urinary frequency; rs7720298, rs673783, rs62091368, and rs144596911 associated with decreased urine stream.

Regions of linkage disequilibrium (LD) were defined for the three loci tagged by SNPs reaching genome-wide significance. rs17599026, associated with urinary frequency, tags a 106 kb region of LD (base position 137,657,783--137,763,798; [Fig. 2](#f0010){ref-type="fig"}A) containing part of *KDM3B* (including the promoter region through exon 20), the upstream *FAM53C*, and part of the upstream *CDC25C* (the promoter region through exon 6). rs7720298, associated with decreased urine stream, tags a 39 kb region of LD (base position 13,858,328--13,897,362; [Fig. 2](#f0010){ref-type="fig"}B) that contains exons 16 through 30 of *DNAH5*. rs11230328 was not in strong linkage disequilibrium with any other common SNPs found in the more recent release of the 1000 Genomes population data, and this locus may represent a spurious association. rs11230328 lies within a LINE element, and may be difficult to map in the genome due to its location within a region of high homology. Imputation coverage (i.e. the number of SNPs successfully imputed in the study datasets out of common SNPs (MAF ≥ 0.05) within the 1000 Genomes European population) was high within the regions tagged (correlation r2 ≥ 0.5) by rs17599026 (173/183, 94.5%) and rs7720298 (130/136, 95.6%).

SNPs rs17599026 and rs7720298 are located in non-coding regions, as is common in GWAS, and the LD blocks tagged by these SNPs cover coding and non-coding regions. rs17599026, associated with urinary frequency, lies in an intronic region 23 bp downstream of exon 20 of *KDM3B* (MIM [609373](609373){#ir0030}; NM_016604.3:c4753 + 23C \> T) encoding the lysine-specific demethylase 3B protein. *KDM3B* is highly expressed in bladder tissue from the Human Protein Atlas project ([@bb0300]), suggesting that this gene could be involved in normal bladder function and potentially dysfunction following damage from radiation exposure. rs17599026 itself does not lie in a site of known transcription factor binding or chromatin modification from the Encyclopedia of DNA Elements (ENCODE) catalog ([@bb0090]) and there are no significant expression quantitative trail loci (eQTLs) for this SNP in the Genotype-Tissue Expression (GTEx) project ([@bb0125]). Given that rs17599026 is very close to exon 20, it could have an effect on splicing. However, no significant splicing motif alteration was detected using Human Splicing Finder ([@bb0080]). ENCODE data show that the large LD block tagged by this SNP contains multiple transcription factor binding sites, DNase hypersensitive sites, histone methylation sites (methylation of lysine 4 at histone 3, H3K4Me3 and methylation of lysine 4 at histone 1, H3K4Me1), and histone acetylation sites (acetylation of lysine 27 at histone 3, H3K27Ac) that may affect regulation of the nearby genes. rs7720298, associated with decreased urine stream, lies in an intronic region just downstream of exon 30 of *DNAH5* (MIM [603335](603335){#ir0035}; NM_001369.2:c.4950 + 1233G \> C) encoding the dynein, axonemal, heavy chain 5 protein that is part of a microtubule-associated motor protein complex. Rare mutations in *DNAH5* can result in development of abnormal cilia and flagella in cells that lead to primary ciliary dyskinesia, which is a disorder characterized in part by chronic respiratory tract infections ([@bb0095]). In addition to playing an important role in the lung, *DNAH5* is expressed in both kidney and bladder tissue, suggesting a biologic role in normal function of the urinary tract ([@bb0300]). This SNP does not lie in a site of known transcription factor binding or chromatin modification from the ENCODE catalog nor is it an eQTL based on data from GTEx, but the region of LD tagged by rs7720298 contains several transcription factor binding sites and sites of DNase hypersensitivity measured in ENCODE cell lines, suggesting that it may tag a site of transcriptional regulation.

4. Discussion & Conclusions {#s0045}
===========================

This meta-analysis aimed to identify SNPs associated with late radiotherapy toxicity in a single tumor site. By having a total sample size in a single stage analysis of \> 1500 men with prostate cancer (versus \~ 600 in published studies), the study identified two risk loci. This study had ≥ 99% power to identify common SNPs (MAFs ≥ 10%) that confer a relatively large increased risk for developing late toxicity (OR ≥ 2.0). Identification of multiple loci in this single-stage meta-analysis versus single loci in published GWAS that used a staged approach is consistent with the increased power. The meta-analysis showed that heterogeneity in radiotherapy datasets is not a barrier for future multi-cohort radiogenomic studies. The absence of significant SNPs associated with rectal bleeding is consistent with the relatively limited statistical power. Most common variants identified via GWAS have more modest effects (ORs 1.15 to 1.5) than this study was powered to detect. Our group previously reported an excess of associations at the p \< 5 × 10^− 7^ level for rectal bleeding showing many SNPs should be identified as sample sizes increase ([@bb0020]). In addition, our current approach of dichotomizing toxicity at grade 0 versus grade 1 or worse and considering two years of follow-up may not be optimal for rectal bleeding, which could be explored as our radiogenomic cohorts increase.

The significant SNPs lie in non-coding regions, as is common in GWAS where \~ 64% of identified SNPs lie in enhancer regions ([@bb0140]). Gene enhancer elements are noncoding segments of DNA involved in regulating transcriptional programs ([@bb0055]). Their location is predicted by DNase I hypersensitive regions of open chromatin flanked by sties of histone methylation. These enhancers can be active (associated with the acylation of lysine 27 of histone 3 \[H3K27Ac\]) or repressed (correlated with histone marks H3K27Me3 and H3K9Me3). Although premature to speculate on the functional consequences of these SNPs, they lie in intronic regions of genes that are expressed in tissues exposed to radiation during treatment of prostate cancer and are involved in the symptoms experienced by men having radiotherapy for this malignancy. Fine mapping studies and functional characterization of causal variants contained within these loci should expand our understanding of the biology underlying the pathogenesis of radiotherapy toxicity.

rs17599026 was genotyped to check the quality of the imputed data from RADIOGEN and RAPPER. Direct genotyping confirmed the high quality of the imputation, but we were unable to genotype directly the other two SNPs for which imputed data were used for all four cohorts. rs7720298 had high imputation information scores (\> 0.95) in all three studies of urinary decreased stream, lending confidence to this association. However, rs11230328 had a lower imputation quality (\< 0.70) in two of the four studies of overall toxicity, and it is not present in the latest 1000 Genomes Project release (v5a; 05/02/2013). Thus, rs11230328 may represent a spurious association.

None of the previously studied candidate gene SNPs for radiotherapy toxicity were among the top loci identified in this meta-analysis, consistent with a recent validation study showing no evidence for association between 92 candidate SNPs and radiotherapy toxicity among \~ 1600 individuals treated with radiotherapy for breast or prostate cancer ([@bb0010]). No SNP discovered in previous GWAS was identified in this de novo analysis, likely due to methodological differences. The published locus on chr2q24.1, identified in RADIOGEN and replicated in RAPPER and Gene-PARE ([@bb0110]), was excluded because the MAFs of the tagging SNPs were \< 5%, the threshold set in this meta-analysis to maximize statistical power. Subsequent to the meta-analysis, we tested SNPs in the chr2q24.1 locus for replication in CCI (the only cohort not included in the initial publication) using the methods of the originally published paper. All seven previously reported SNPs showed a consistent direction of association with overall toxicity in CCI, and rs264651 showed a statistically significant association (linear regression beta = 0.66; 95% CI 0.06, 1.27; p-value = 0.03). The locus was also tested for association with the three individual toxicity endpoints investigated in this paper, and appeared to be predominantly associated with urinary toxicity (Table S5). SNPs rs7582141, rs6432512, rs264588, and rs264631 were significantly associated with an increased risk for decreased urinary stream and increased urinary frequency (meta-analysis p-values \< 0.05, Table S5). The directions of the associations were consistent across the other three SNPs, with rs264663 and rs264651 reaching statistical significance for urinary frequency. The direction of the association of six of the seven SNPs was consistent for the rectal bleeding endpoint, but none of the SNPs approached statistical significance, suggesting that the urinary endpoints are predominantly driving the association of this locus with overall toxicity. This finding thus supports the initial report that chr2q24.1 is a risk locus for late radiotherapy toxicity in prostate cancer. rs7120482 on chr11q14.3 was previously identified in Gene-PARE and replicated in a combined dataset that included RADIOGEN and CCI ([@bb0175]), but the association with rectal bleeding was restricted to a recessive inheritance model. In this meta-analysis, dominant and recessive models were not considered in order to avoid an increased burden of multiple comparisons correction. Subsequent to this meta-analysis, we tested rs7120482 for replication in RAPPER (the only cohort not included in that initial publication) using the methods of the originally published paper. The initial association with rectal bleeding was not replicated in RAPPER (odds ratio = 0.74; 95% CI 0.08, 7.33; p-value = 0.79). This lack of replication could be due to differences in the radiotherapy regimen or scoring of toxicity - the incidence of rectal bleeding was low in RAPPER (3%) compared with the other studies (10% to 18%). However, the initial association fell just short of genome-wide significance and might be a false positive result. At this early stage of radiogenomic GWAS we expect some initial associations to be lost as sample sizes increase and false-positive findings are reduced, as seen in other GWAS meta-analyses ([@bb0100]). Finally, Gene-PARE previously identified risk SNPs for erectile dysfunction ([@bb0165], [@bb0170]), but this endpoint was not assessed in the other studies in the meta-analysis. Thus, previously identified SNPs remain important, and the meta-analysis reports additional loci.

This study has several strengths. First, toxicity was assessed prospectively in all four studies, which minimizes recall bias. Second, baseline information ensures any SNP-toxicity associations identified occur because of the radiotherapy rather than any pre-existing (possibly tumor-related) symptoms. Third, a multivariable approach accounted for relevant treatment and clinical variables. Radiogenomics involves phenotypes that occur in response to an environmental exposure (i.e. therapeutic radiation) that is measurable and can be adjusted for. Fourth, reliable and current imputation methods were used to obtain comparable and dense SNP maps across the four studies, allowing meta-analysis of studies involving different SNP genotyping platforms. Without imputation, only 15,144 SNPs were common to all four datasets, reducing the likelihood of identifying SNPs associated with late radiotherapy toxicity.

This study has limitations. First, the four studies were designed independently and involved different methods for recording toxicity. Endpoints needed harmonizing and the approach might be sub-optimal, but serves as a useful guide for future radiogenomics studies involving multiple cohorts. Although endpoints were dichotomized to minimize differences in toxicity grades across the cohorts, the simulation experiment showed minimal loss of statistical power. Second, there was the heterogeneity in radiotherapy protocols. For example, Gene-PARE included individuals who received brachytherapy with EBRT, which increases urinary toxicity ([@bb0250]). Similarly, the proportion of individuals who received androgen deprivation differed across the studies. This heterogeneity was adjusted for using multivariable analysis and by a meta-analysis approach. Importantly, none of the top SNPs showed evidence of heterogeneity in effect size across studies ([Table 5](#t0025){ref-type="table"}, [Table 6](#t0030){ref-type="table"}, [Table 7](#t0035){ref-type="table"}, [Table 8](#t0040){ref-type="table"}). The first SNPs identified are those that rise above such noise in the data, and the significance of our work is that we can find variants despite imperfect datasets. We attempted to control for differences in radiation dose by adjusting for total biologically effective dose in each GWAS. However, this is a surrogate for the doses received by specific normal tissues. Future cohorts with detailed dosimetry data to the different organs at risk will improve on our ability to identify SNPs. The heterogeneity in cohorts should be embraced, as any predictive test must use SNPs that are associated with toxicity across treatment centers and protocols. Last, in order to minimize confounding by population structure, the present analysis was restricted to individuals of European ancestry. It will be important for future studies to focus on other ancestral groups, both for replication of the loci identified here and for discovery of additional loci.

While this study was successful in identifying radiosensitivity SNPs via a meta-analysis of GWAS, it is modestly sized compared with GWAS of other diseases and traits, and it should be viewed as the starting point for expanded radiogenomics studies. Given that our study was not powered to detect SNPs with odds ratio \< 2, many true positive SNPs will have been missed. Also, though the SNPs identified here reach statistical significance and show consistency across multiple independent studies, there is still a possibility that they will fail to replicate in other cohorts. This is a challenge in GWAS ([@bb0210]), but meta-analysis and replication studies have proved successful in validating hundreds of risk SNPs for a wide variety of diseases and phenotypes. Future large GWAS meta-analyses will identify additional SNPs, and this work is underway. The Radiogenomics Consortium is a participant in the OncoArray Network, which is a large collaborative effort to gain new insight into the genetic architecture and mechanisms underlying several cancers as well as outcomes related to the their treatment. Approximately 5000 additional DNA samples from individuals treated with radiotherapy for prostate cancer are being genotyped using the customized OncoArray, and meta-analysis of this greatly expanded set of GWAS data using the methods developed in this paper will uncover additional risk SNPs, provide a platform for further validation of the SNPs identified here, and serve as the basis for future post-GWAS analyses on these confirmed loci.

The last decade saw a rapid expansion of knowledge of the genetics of disease susceptibility in the general population. Numerous large collaborative GWAS showed that polygenic risk profiles can be built based on multiple SNPs each conferring small effects but together a significant proportion of susceptibility to common diseases. With the rapid decline in costs for genetic testing, there is growing acceptance that risk prediction models incorporating genetic and environmental factors will be important in future healthcare provision ([@bb0040]). In 2012 there were an estimated 32.6 million people alive five years after being diagnosed with cancer (<http://www.cdc.gov/cancer/international/statistics.htm>), and many will be living with the consequences of treatment. Research developing models predicting susceptibility to long-term radiation effects is important and the findings reported here shows that heterogeneous radiotherapy cohorts can be combined to identify common genetic variants associated with toxicity. The work provides a basis for larger collaborative efforts to identify enough variants for a future test involving polygenic risk profiling.
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![Forest plots of significant SNPs. SNPs with meta-p-value \< 5 × 10^− 8^ associated with: (a) urinary frequency (rs17599026); (b) decreased urine stream (rs7720298); and (c) overall toxicity (rs11230328). p-Values are from meta-analysis of regression coefficients and standard errors from regression analysis performed in each study. Odds ratios (OR; urinary frequency and decreased urine stream) or regression beta coefficient (STAT score) are shown for each individual study as well as the meta-analysis (Summary). The size of the box marking each odds ratio or beta is proportional to the precision of estimate for the given study. Lines on the boxes denote 95% confidence intervals. 'Toxicity' and 'No toxicity' (rs17599026 and rs7720298) was defined as ≥ 1 point increase in toxicity grade versus no change in toxicity grade from pre-radiotherapy scores. Overall toxicity was analyzed as a continuous variable (STAT).](gr1){#f0005}

![Regional plots for two loci. Loci tagged by rs17599026 (a) and rs7720298 (b) with points representing the tag SNP reported in this paper shown in purple circles. Points representing nearby SNPs are color coded according to linkage disequilibrium r^2^ value as indicated in the legends. The recombination rate is estimated from samples from the International HapMap project.](gr2){#f0010}

###### 

Number of individuals in each cohort.

Table 1

                                                                     RAPPER   RADIOGEN                               Gene-PARE                              CCI
  ------------------------------------------------------------------ -------- -------------------------------------- -------------------------------------- --------------------------------------
  Total in cohort                                                    727      741                                    895                                    155
  Genotyped via genome-wide SNP chip                                 672      741                                    381                                    155
   Excluded: \> 5% SNPs missing                                      18       1                                      8                                      1
   Excluded: cryptic relatedness                                     14       19                                     16                                     0
   Excluded: excess heterozygosity                                   19       --                                     --                                     --
   Excluded: PCA outlier                                             --       68                                     --                                     --
   Excluded: non-European ancestry based on PCA w/ HapMap samples    21       1                                      67                                     3
   Excluded: lacking all 2 yr toxicity or essential covariate data   73       55                                     0                                      1
  Number included in analysis of at least one toxicity endpoint      527      597[a](#tf0005){ref-type="table-fn"}   290[b](#tf0010){ref-type="table-fn"}   150[c](#tf0015){ref-type="table-fn"}

Additional follow-up of the RADIOGEN cohort increased the number with late toxicity data available from the 417 reported previously ([@bb0110]). Of the 597 participants in RADIOGEN, one lacked data on rectal toxicity and seven data on rectal volume and were excluded from the analysis of rectal bleeding. 120 participants had no data on baseline urinary frequency and 119 were missing data on decreased urine stream and were excluded from the respective analyses.

Of the 290 participants in Gene-PARE, 55 were lacking data for rectal volume and were excluded from analysis of rectal bleeding. 35 participants did not complete the urinary questionnaire and were excluded from analysis of urinary frequency and decreased urine stream.

Of the 150 participants in CCI, 15 were lacking data for rectal volume or diabetes and were excluded from analysis of rectal bleeding.

###### 

Individual study patient characteristics.

Table 2

                                                                  RAPPER, N = 527                       RADIOGEN, N = 597   Gene-PARE, N = 290   CCI, N = 151
  --------------------------------------------------------------- ------------------------------------- ------------------- -------------------- --------------
  Age, mean (sd[a](#tf0020){ref-type="table-fn"})                 67 (5.7)                              71 (5.8)            64 (7.5)             67 (7.2)
  TURP[b](#tf0025){ref-type="table-fn"}, n (%)                    56 (11%)                              45 (8%)             6 (2%)               6 (4%)
  Diabetes, n (%)                                                 39 (7%)                               144 (24%)           16 (6%)              24 (16%)
  Gleason score, n (%)                                                                                                                           
   ≤ 6                                                            261 (50%)                             366 (61%)           193 (67%)            30 (20%)
   7                                                              231 (44%)                             164 (28%)           69 (24%)             97 (64%)
   ≥ 8                                                            25 (5%)                               60 (10%)            28 (10%)             21 (14%)
   missing                                                        10 (2%)                               7 (1%)              0                    3 (2.0%)
  Stage, n (%)                                                                                                                                   
   T1                                                             187 (35%)                             214 (35.8%)         150 (52%)            38 (25%)
   T2                                                             267 (51%)                             323 (54.1%)         128 (44%)            89 (59%)
   T3                                                             61 (10%)                              44 (7.4%)           12 (4%)              16 (11%)
   T4                                                             0                                     0                   0                    1 (1%)
   missing                                                        12 (2%)                               17 (2.8%)           0                    7 (5%)
  Pre-treatment PSA[c](#tf0030){ref-type="table-fn"}, mean (sd)   13.2 (7.5)                            16 (20.5)           9.4 (19.4)           15.5 (13.4)
  Hormone therapy, n (%)                                          527 (100%)                            415 (69.5)          147 (51%)            74 (49%)
  BED[d](#tf0035){ref-type="table-fn"}, mean (sd)                 120.5 (6.2)                           120.5 (5.8)         191.9 (22.4)         125.5 (6.2)
  Rectum Volume (cm^3^), mean (sd)                                NA[e](#tf0040){ref-type="table-fn"}   56.9 (29.9)         33.9 (13.9)          76.3 (27.7)

sd, standard deviation.

TURP, transurethral resection of the prostate.

PSA, prostate specific antigen.

BED, biologically effective dose.

NA, not available.

###### 

Prevalence of radiotherapy toxicity endpoints.

Table 3

                           Change in toxicity grade from baseline[a](#tf0045){ref-type="table-fn"}                          
  ------------------------ ------------------------------------------------------------------------- ----------- ---------- -----------
  Rectal bleeding                                                                                                           
  RAPPER                   446 (85%)                                                                 64 (12%)    16 (3%)    1 (\< 0%)
  RADIOGEN                 516 (88%)                                                                 52 (9%)     16 (3%)    5 (1%)
  Gene-PARE                208 (72%)                                                                 25 (9%)     49 (17%)   8 (3%)
  CCI                      110 (73%)                                                                 29 (19%)    6 (4%)     6 (4%)
                                                                                                                            
  Urinary frequency                                                                                                         
  RAPPER                   482 (91%)                                                                 42 (8%)     3 (1%)     0
  RADIOGEN                 423 (89%)                                                                 46 (10%)    7 (2%)     1(\< 1%)
  Gene-PARE                173 (68%)                                                                 52 (20%)    25 (10%)   5 (2%)
  CCI                      120 (80%)                                                                 24 (16%)    7 (5%)     0
                                                                                                                            
  Decreased urine stream                                                                                                    
  RAPPER                   483 (94%)                                                                 18 (4%)     9 (2%)     2 (\< 1%)
  RADIOGEN                 472 (99%)                                                                 2 (\< 1%)   3 (1%)     1 (\< 1%)
  Gene-PARE                189 (74%)                                                                 34 (13%)    24 (9%)    8 (3%)
  CCI                      NA                                                                        NA          NA         NA

For the Gene-PARE, CCI and RADIOGEN studies, the post-treatment rectal bleeding grade already accounts for baseline symptoms. For the CCI study, the post-treatment urinary frequency grade already accounts for baseline symptoms.

###### 

Power to detect significant associations among 1564 radiotherapy patients[a](#tf0050){ref-type="table-fn"}.

Table 4

                          Minor allele frequency                                     
  ----------------------- ------------------------ ----- ------ ------ ------ ------ ---
  Per-allele odds ratio   1.15                     0     0      0      0      0      0
  1.25                    0                        0     0      1%     1%     1%     
  1.5                     1%                       7%    21%    47%    59%    56%    
  2.0                     64%                      99%   100%   100%   100%   100%   

Assuming a type I error rate of 5 × 10^− 8^ and a disease prevalence of 20%, which was the approximate average prevalence of the toxicities included in the study.

###### 

Rectal bleeding multivariable analysis results (p \< 5 × 10^− 6^).

Table 5

  rsID                                           Chr       Minor allele   MAF[a](#tf0055){ref-type="table-fn"}   RAPPER, N = 527    RADIOGEN, N = 589   Gene-PARE, N = 235                    CCI, N = 136     Meta-analysis, N = 1487                                                                                                
  ---------------------------------------------- --------- -------------- -------------------------------------- ------------------ ------------------- ------------------------------------- ---------------- ------------------------- ---------------- ------------------- ------- ---------------------- ------------------------ -------
  rs12497518                                     3p12.3    A              0.47                                   0.66 (0.45,0.95)   0.025               0.60 (0.41,0.87)                      5.44 × 10^− 3^   0.52 (0.33,0.84)          5.67 × 10^− 3^   0.58 (0.34,0.97)    0.035   **0.60 (0.48,0.74)**   **1.41 × 10**^**− 6**^   0.903
  rs141044160[e](#tf0075){ref-type="table-fn"}   23q23     C              0.05                                   2.62 (1.53,4.48)   7.86 × 10^− 4^      NA[f](#tf0080){ref-type="table-fn"}   NA               2.77 (1.48,5.21)          1.06 × 10^− 3^   NA                  NA      **2.68 (1.78,4.04)**   **2.26 × 10**^**− 6**^   0.892
  rs7432328[g](#tf0085){ref-type="table-fn"}     3p26.1    A              0.06                                   3.15 (1.78,5.58)   1.34 × 10^− 4^      NA                                    NA               NA                        NA               4.32 (1.40,13.29)   0.011   **3.36 (2.02,5.59)**   **3.23 × 10**^**− 6**^   0.620
  rs6999859                                      8q21.13   G              0.28                                   1.73 (1.15,2.61)   9.00 × 10^− 3^      2.10 (1.40,3.16)                      4.12 × 10^− 4^   1.36 (0.84,2.20)          0.219            1.6 (0.86,2.99)     0.138   **1.73 (1.37,2.17)**   **3.42 × 10**^**− 6**^   0.592
  rs4804134                                      19p13.2   G              0.31                                   0.63 (0.44,0.91)   0.011               0.48 (0.32,0.71)                      1.58 × 10^− 4^   0.69 (0.42,1.12)          0.131            0.68 (0.38,1.22)    0.186   **0.60 (0.48,0.74)**   **3.47 × 10**^**− 6**^   0.621
  rs360071                                       1q42.12   T              0.49                                   1.69 (1.20,2.40)   2.80 × 10^− 3^      1.77 (1.23,2.54)                      2.08 × 10^− 3^   1.43 (0.92,2.23)          0.110            1.40 (0.82,2.38)    0.217   **1.61 (1.32,1.97)**   **3.62 × 10**^**− 6**^   0.835

MAF, minor allele frequency.

OR, odds ratio.

CI, confidence interval.

phet = p-value from chi-squared test of heterogeneity.

For rs141044160, RADIOGEN MAF = 0.048, imputation info = 0.749, OR (95% CI) = 0.81, (0.36, 1.81), p-value = 0.593 and CCI = Not imputed.

NA, not available.

For rs7432328, RADIOGEN MAF = 0.030, imputation info = 0.946, OR (95%CI) = 0.37 (0.08, 1.65), p-value = 0.134; Gene-PARE MAF = 0.041, imputation info = 0.953, OR (95% CI) = 0.91 (0.33, 2.52), p-value = 0.735.

###### 

Urinary frequency multivariable analysis results (p \< 5 × 10^− 6^).

Table 6

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  rsID                                         Chr        Minor allele   MAF[a](#tf0090){ref-type="table-fn"}   RAPPER, N = 527    RADIOGEN, N = 477   Gene-PARE, N = 255   CCI, N = 150     Meta-analysis, N = 1409                                                                                                                           
  -------------------------------------------- ---------- -------------- -------------------------------------- ------------------ ------------------- -------------------- ---------------- ------------------------- ---------------- ------------------------------------- ---------------- ---------------------- ------------------------ -------
  rs17599026                                   5q31.2     T              0.08                                   2.57 (1.28,5.16)   0.012               3.19 (1.57,6.46)     2.36 × 10^− 3^   8.16 (3.04,21.9)          5.88 × 10^− 6^   1.63\                                 0.358            **3.12 (2.08,4.69)**   **4.16 × 10**^**− 8**^   0.139
                                                                                                                                                                                                                                        (0.59,4.54)                                                                                            

  rs11574532                                   12q13.13   T              0.07                                   1.70 (0.70,4.33)   0.282               3.69 (1.78,7.68)     8.29 × 10^− 4^   3.57 (1.53,8.35)          3.03 × 10^− 3^   5.76 (1.66,19.99)                     5.50 × 10^− 3^   **3.25 (2.08,5.07)**   **2.11 × 10**^**− 7**^   0.420

  rs342442                                     4q22.1     T              0.38                                   0.39 (0.22,0.68)   3.50 × 10^− 4^      0.56 (0.36,0.89)     0.011            0.51 (0.32,0.8)           2.88 × 10^− 3^   0.62\                                 0.174            **0.51 (0.39,0.66)**   **3.86 × 10**^**− 7**^   0.700
                                                                                                                                                                                                                                        (0.31,1.25)                                                                                            

  rs4534636                                    12p13.31   A              0.20                                   1.27 (0.71,2.27)   0.429               2.48 (1.54,3.99)     2.35 × 10^− 4^   2.06 (1.25,3.41)          4.31 × 10^− 3^   2.03\                                 0.0461           **1.96 (1.49,2.59)**   **1.67 × 10**^**− 6**^   0.373
                                                                                                                                                                                                                                        (0.97,4.25)                                                                                            

  rs8098701                                    18q21.1    T              0.07                                   2.93 (1.39,6.15)   7.63 × 10^− 3^      2.75 (1.52,4.97)     1.15 × 10^− 3^   1.70 (0.86,3.34)          0.133            2.53\                                 0.136            **2.41 (1.68,3.47)**   **2.11 × 10**^**− 6**^   0.684
                                                                                                                                                                                                                                        (0.77,8.28)                                                                                            

  rs7366282[e](#tf0110){ref-type="table-fn"}   1q41       C              0.06                                   2.22 (1.02,4.82)   0.056               4.11 (1.82,9.3)      1.27 × 10^− 3^   3.86 (1.55,9.63)          3.03 × 10^− 3^   NA[f](#tf0115){ref-type="table-fn"}   NA               **3.20 (1.98,5.16)**   **2.03 × 10**^**− 6**^   0.501

  rs10209697                                   2q36.1     A              0.07                                   4.09 (1.65,10.1)   4.35 × 10^− 3^      4.32 (2.19,8.5)      5.14 × 10^− 5^   1.53 (0.74,3.14)          0.255            1.36\                                 0.599            **2.66 (1.77,3.99)**   **2.27 × 10**^**− 6**^   0.093
                                                                                                                                                                                                                                        (0.44,4.27)                                                                                            

  rs4997823                                    6q14.1     G              0.35                                   0.40 (0.22,0.74)   1.90 × 10^− 3^      0.37 (0.2,0.67)      5.69 × 10^− 4^   0.68 (0.42,1.11)          0.118            0.44\                                 0.040            **0.49 (0.36,0.66)**   **2.35 × 10**^**− 6**^   0.372
                                                                                                                                                                                                                                        (0.20,0.99)                                                                                            

  rs7356945                                    6p24.1     T              0.33                                   2.56 (1.58,4.13)   1.10 × 10^− 4^      1.63 (1.08,2.48)     0.022            1.21 (0.8,1.85)           0.368            2.42\                                 7.32 × 10^− 3^   **1.74 (1.38,2.21)**   **3.71 × 10**^**− 6**^   0.097
                                                                                                                                                                                                                                        (1.25,4.69)                                                                                            

  rs6003982                                    22q11.23   G              0.44                                   0.67 (0.37,1.19)   0.166               0.46 (0.27,0.79)     3.70 × 10^− 3^   0.39 (0.23,0.67)          4.33 × 10^− 6^   0.60\                                 0.138            **0.51 (0.38,0.68)**   **4.28 × 10**^**− 6**^   0.549
                                                                                                                                                                                                                                        (0.30,1.19)                                                                                            

  rs10101158                                   8q24.3     A              0.44                                   1.63 (0.95,2.81)   0.074               1.56 (0.98,2.48)     0.063            1.99 (1.3,3.06)           1.24 × 10^− 3^   2.17\                                 0.015            **1.80 (1.40,2.31)**   **4.39 × 10**^**− 6**^   0.792
                                                                                                                                                                                                                                        (1.14,4.11)                                                                                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MAF, minor allele frequency.

OR, odds ratio.

CI, confidence interval.

phet = p-value from chi-squared test of heterogeneity.

rs7366282 was not imputed in CCI.

NA, not available.

###### 

Decreased stream multivariable analysis results (p \< 5 × 10^− 6^).

Table 7

  rsID                                          Chr        Minor allele   MAF[a](#tf0120){ref-type="table-fn"}   RAPPER, N = 512     RADIOGEN, N = 478   Gene-PARE, N = 255                    Meta-analysis, N = 1245                                                                                       
  --------------------------------------------- ---------- -------------- -------------------------------------- ------------------- ------------------- ------------------------------------- ------------------------- ------------------ ---------------- ---------------------- ------------------------ -------
  rs7720298                                     5p15.2     G              0.24                                   2.13 (1.21,3.74)    0.010               3.63 (1.08,12.16)                     0.044                     3.09 (1.9,5.04)    2.34 × 10^− 6^   **2.71 (1.90,3.86)**   **3.21 × 10**^**− 8**^   0.545
  rs17362923[e](#tf0140){ref-type="table-fn"}   8p23.2     G              0.18                                   3.60 (1.98,6.55)    3.12 × 10^− 5^      NA[f](#tf0145){ref-type="table-fn"}   NA                        2.18 (1.29,3.66)   3.20 × 10^− 3^   **2.70 (1.83,4.00)**   **6.79 × 10**^**− 7**^   0.459
  rs76273496                                    1q31.3     C              0.07                                   4.02 (1.83,8.81)    1.31 × 10^− 3^      3.69 (0.66,20.46)                     0.169                     3.32 (1.43,7.68)   5.13 × 10^− 3^   **3.68 (2.13,6.33)**   **2.71 × 10**^**− 6**^   0.948
  rs2203205                                     23q21.1    C              0.29                                   1.70 (1.15,2.52)    0.010               2.35 (0.97,5.74)                      0.054                     1.71 (1.26,2.31)   5.87 × 10^− 4^   **1.74 (1.38,2.20)**   **2.86 × 10**^**− 6**^   0.790
  rs144596911                                   3q28       A              0.09                                   4.41 (2.09,9.28)    2.38 × 10^− 4^      1.01 (0.09,11.12)                     0.995                     3.28 (1.44,7.45)   4.78 × 10^− 3^   **3.60 (2.11,6.17)**   **2.94 × 10**^**− 6**^   0.493
  rs62091368                                    18p11.32   A              0.07                                   6.78 (2.26,20.37)   1.26 × 10^− 3^      6.96 (1.71,28.3)                      0.015                     2.66 (1.08,6.57)   0.037            **4.36 (2.33,8.14)**   **3.95 × 10**^**− 6**^   0.334
  rs141342719                                   5q23.3     T              0.12                                   5.39 (2.43,11.94)   5.09 × 10^− 5^      1.35 (0.23,7.9)                       0.748                     2.77 (1.27,6.07)   0.012            **3.50 (2.05,5.95)**   **3.97 × 10**^**− 6**^   0.273
  rs673783                                      18p11.32   G              0.31                                   2.88 (1.52,5.44)    1.06 × 10^− 3^      2.28 (0.68,7.6)                       0.183                     2.28 (1.33,3.91)   3.24 × 10^− 3^   **2.49 (1.69,3.67)**   **4.33 × 10**^**− 6**^   0.853

MAF, minor allele frequency.

OR, odds ratio.

CI, confidence interval.

phet = p-value from chi-squared test of heterogeneity.

For rs17362923, RADIOGEN MAF = 0.182; imputation info = 0.980. This SNP had a very large standard error in the RADIOGEN dataset, and so it was excluded from meta-analysis.

NA, not available.

###### 

Overall toxicity (STAT) multivariable analysis results (p \< 5 × 10^− 6^).

Table 8.

  rsID                                           Chr        Minor allele   MAF[a](#tf0150){ref-type="table-fn"}   RAPPER, N = 527                       RADIOGEN, N = 474   Gene-PARE, N = 209   CCI, N = 136     Meta-analysis, N = 1,346                                                                                                 
  ---------------------------------------------- ---------- -------------- -------------------------------------- ------------------------------------- ------------------- -------------------- ---------------- -------------------------- ---------------- ---------------------- ---------------- ------------------ ----------------- -------
  rs11230328                                     11q12.2    G              0.27                                   0.23 (0.06,0.40)                      7.96 × 10^− 3^      0.45 (0.29,0.61)     3.50 × 10^− 8^   0.20 (− 0.03,0.43)         0.083            0.22 (− 0.09,0.53)     0.170            0.31 (0.21,0.41)   6.27 × 10^− 10^   0.154
  rs147596965[d](#tf0165){ref-type="table-fn"}   10p14      T              0.07                                   NA[e](#tf0170){ref-type="table-fn"}   NA                  0.75 (0.47,1.03)     2.73 × 10^− 7^   NA                         NA               0.44 (− 0.04,0.92)     0.072            0.67 (0.43,0.91)   6.19 × 10^− 8^    0.150
  rs77530448                                     2q31.1     G              0.09                                   0.07 (− 0.18,0.33)                    0.576               0.51 (0.31,0.71)     4.01 × 10^− 7^   0.41 (0.12,0.70)           5.60 × 10^− 3^   0.29 (− 0.13,0.70)     0.179            0.36 (0.23,0.49)   7.36 × 10^− 8^    0.060
  rs4906759[f](#tf1030){ref-type="table-fn"}     15q12      T              0.06                                   0.34 (− 0.02,0.71)                    0.063               0.86 (0.54,1.18)     2.28 × 10^− 7^   0.32 (− 0.08,0.72)         0.110            NA                     NA               0.55 (0.34,0.75)   1.55 × 10^− 7^    0.047
  rs71610881[g](#tf0180){ref-type="table-fn"}    4p15.2     A              0.06                                   0.70 (0.42,0.97)                      1.30 × 10^− 6^      NA                   NA               NA                         NA               0.36 (− 0.06,0.79)     0.098            0.60 (0.36,0.83)   5.41 × 10^− 7^    0.198
  rs141799618[h](#tf0185){ref-type="table-fn"}   19q13.2    G              0.06                                   0.33 (0.02,0.65)                      0.039               0.50 (0.26,0.74)     5.17 × 10^− 5^   NA                         NA               0.45 (− 0.04,0.94)     0.072            0.44 (0.26,0.62)   1.22 × 10^− 6^    0.698
  rs2842169                                      10q26.2    C              0.10                                   0.33 (0.12,0.53)                      1.73 × 10^− 3^      0.24 (0.07,0.41)     7.54 × 10^− 3^   0.28 (− 0.02,0.58)         0.067            0.39 (− 0.02,0.81)     0.065            0.28 (0.17,0.40)   1.45 × 10^− 6^    0.863
  rs11219068                                     11q24.1    A              0.15                                   0.38 (0.17,0.59)                      3.56 × 10^− 4^      0.18 (− 0.01,0.37)   0.062            0.16 (− 0.11,0.43)         0.252            0.49 (0.18,0.79)       2.25 × 10^− 3^   0.28 (0.17,0.40)   1.74 × 10^− 6^    0.204
  rs8075565                                      17p13.2    T              0.13                                   0.37 (0.16,0.59)                      6.43 × 10^− 4^      0.33 (0.14,0.52)     5.91 × 10^− 4^   0.23 (− 0.03,0.49)         0.080            − 0.01 (− 0.33,0.30)   0.933            0.28 (0.16,0.39)   2.20 × 10^− 6^    0.217
  rs6535028                                      4q28.3     T              0.10                                   0.22 (0.02,0.43)                      0.031               0.33 (0.14,0.52)     8.62 × 10^− 4^   0.42 (0.11,0.73)           8.13 × 10^− 3^   0.16 (− 0.19,0.51)     0.374            0.29 (0.17,0.40)   2.70 × 10^− 6^    0.615
  rs4775602                                      15q21.1    C              0.16                                   0.12 (− 0.04,0.28)                    0.135               0.27 (0.12,0.42)     5.54 × 10^− 4^   0.40 (0.17,0.63)           7.39 × 10^− 4^   0.11 (− 0.23,0.44)     0.525            0.23 (0.13,0.32)   3.02 × 10^− 6^    0.240
  rs60481745                                     1p13.3     A              0.10                                   0.20 (− 0.07,0.46)                    0.149               0.39 (0.14,0.64)     2.69 × 10^− 3^   0.65 (0.22,1.08)           3.11 × 10^− 3^   0.57 (0.08,1.05)       0.022            0.37 (0.22,0.53)   3.53 × 10^− 6^    0.260
  rs7829759                                      8p23.2     A              0.11                                   0.46 (0.23,0.69)                      1.29 × 10^− 4^      0.22 (− 0.02,0.46)   0.078            0.33 (0.02,0.64)           0.042            0.26 (− 0.20,0.72)     0.264            0.33 (0.19,0.47)   3.84 × 10^− 6^    0.551
  rs79604958[i](#tf0190){ref-type="table-fn"}    15q24.2    C              0.07                                   NA                                    NA                  0.35 (0.04,0.66)     0.024            0.44 (0.10,0.78)           0.013            0.77 (0.34,1.21)       6.41 × 10^− 4^   0.47 (0.27,0.68)   4.33 × 10^− 6^    0.289
  rs10770857                                     12p13.31   A              0.37                                   0.18 (0.05,0.31)                      6.02 × 10^− 3^      0.14 (0.02,0.26)     0.017            0.15 (− 0.03,0.33)         0.097            0.28 (0.05,0.51)       0.018            0.17 (0.10,0.25)   4.98 × 10^− 6^    0.774
  rs12591436                                     15q25.1    G              0.34                                   0.23 (0.09,0.37)                      1.56 × 10^− 3^      0.16 (0.04,0.28)     8.79 × 10^− 3^   0.14 (− 0.07,0.35)         0.178            0.20 (− 0.05,0.46)     0.124            0.18 (0.10,0.26)   5.66 × 10^− 6^    0.885

MAF, minor allele frequency.

CI, confidence interval.

phet = p-value from chi-squared test of heterogeneity.

For rs147596965, RAPPER MAF = 0.045, info = 0.619, beta (95%CI) = − 0.14 (− 0.53, 0.25), p-value = 0.478; Gene-PARE MAF = 0.044, info = 0.662, beta (95% CI) = − 0.31 (− 0.83, 0.20), p-value = 0.237.

NA, not available.

For rs4906759, CCI MAF = 0.040, info = 0.604, beta (95% CI) = − 0.71 (− 1.37, − 0.05), p-value = 0.035.

For rs71610881, RADIOGEN MAF = 0.040, info = 0.986, beta (95% CI) = 0.04 (− 0.24, 0.33), p-value = 0.761; Gene-PARE MAF = 0.022, info = 0.995, beta (95% CI) = − 0.07 (− 0.77, 0.63), p-value = 0.841.

For rs141799618, Gene-PARE MAF = 0.037, info = 0.780, beta (95% CI) = − 0.27, (− 0.89, 0.35), p-value = 0.395.

For rs79604958, RAPPER MAF = 0.045, info = 0.499, beta (95% CI) = 0.60 (0.20,1.00), p = 0.0036.

###### 

Ordinal logistic regression results showing association between top SNPs and toxicity grade.

Table 9

  Toxicity endpoint   SNP                 RAPPER             RADIOGEN                              Gene-PARE                                CCI                                      Meta-analysis                                                                                                    
  ------------------- ------------------- ------------------ ------------------------------------- ---------------------------------------- ---------------------------------------- ------------------ ------------------- ------------------ ------------------ ------------------ ---------------- -------
  Rectal bleeding     rs12497518          0.66 (0.45,0.95)   0.023                                 0.60 (0.41,0.87)                         5.41 × 10^− 3^                           0.52 (0.33,0.83)   4.37 × 10^− 3^      0.58 (0.34,0.96)   0.033              0.60 (0.48,0.73)   9.80 × 10^− 7^   0.894
  rs141044160         2.54 (1.52,4.26)    8.70 × 10^− 4^     NA[c](#tf0205){ref-type="table-fn"}   NA                                       2.62 (1.52,4.52)                         7.79 × 10^− 4^     NA                  NA                 2.58 (1.77,3.75)   7.47 × 10^− 7^     0.942            
  rs6999859           1.74 (1.16,2.62)    8.37 × 10^− 3^     2.10 (1.40,3,14)                      3.87 × 10^− 4^                           1.38 (0.86,2.22)                         0.190              1.51 (0.82,2.75)    0.183              1.70 (1.37,2.13)   2.40 × 10^− 6^     0.567            
  rs4804134           0.64 (0.44,0.91)    0.012              0.47 (0.32,0.70)                      1.20 × 10^− 4^                           0.68 (0.42,1.10)                         0.113              0.69 (0.39,1.22)    0.209              0.60 (0.48,0.74)   3.15 × 10^− 6^     0.572            
  rs360071            1.69 (1.19,2.38)    2.83 × 10^− 3^     1.74 (1.21,2.49)                      2.72 × 10^− 3^                           1.43 (0.92,2.22)                         0.108              1.40 (0.83,2.38)    0.213              1.60 (1.31,1.95)   4.34 × 10^− 6^     0.851            
  rs7432328           2.88 (1.67,4.98)    5.29 × 10^− 4^     NA                                    NA                                       NA                                       NA                 3.97 (1.38,11.39)   0.012              3.09 (1.90,5.01)   5.29 × 10^− 6^     0.598            
  Urinary frequency   rs17599026          2.56 (1.28,5.12)   0.012                                 3.77 (1.79,7.64)                         6.97 × 10^− 4^                           4.07 (1.96,8.64)   1.71 × 10^− 4^      1.84 (0.64,4.93)   0.250              3.09 (2.11,4.53)   8.06 × 10^− 9^   0.542
  rs11574532          1.65 (0.65,4.14)    0.308              3.40 (1.64,6.86)                      0.002                                    2.62 (1.23,5.53)                         0.013              4.44 (1.41,13.87)   0.012              2.79 (1.84,4.24)   1.41 × 10^− 6^     0.534            
  rs342442            0.39 (0.22,0.68)    3.57 × 10^− 4^     0.56 (0.35,0.88)                      9.88 × 10^− 3^                           0.54 (0.35,0.83)                         4.48 × 10^− 3^     0.63 (0.31,1.23)    0.183              0.52 (0.40,0.67)   5.57 × 10^− 7^     0.685            
  rs7366282           2.44 (1.11,5.36)    0.036              3.69 (1.62,8.08)                      2.40 × 10^− 3^                           3.80 (1.69,8.40)                         1.44 × 10^− 3^     NA                  NA                 3.25 (2.05,5.14)   4.60 × 10^− 7^     0.681            
  rs4534636           1.28 (0.71,2.28)    0.417              2.50 (1.55,4.03)                      2.05 × 10^− 4^                           2.07 (1.29,3.34)                         2.57 × 10^− 3^     2.18 (1.06,4.49)    0.035              2.00 (1.53,2.62)   4.75 × 10^− 7^     0.361            
  rs8098701           3.01 (1.44,6.31)    6.05 × 10^− 3^     2.59 (1.44,4.54)                      1.79 × 103                               1.46 (0.75,2.74)                         0.252              2.90 (0.87,8.97)    0.080              2.28 (1.60,3.24)   4.40 × 10^− 6^     0.426            
  rs10101158          1.62 (0.94,2.78)    0.077              1.55 (0.98,2.46)                      0.064                                    1.96 (1.31,2.94)                         9.06 × 10^− 4^     2.06 (1.12,3.93)    0.020              1.78 (1.39,2.27)   3.67 × 10^− 6^     0.830            
  rs10209697          3.88 (1.58,9.53)    5.55 × 10^− 3^     3.86 (1.98,7.40)                      1.25 × 10^− 4^                           1.75 (0.86,3.45)                         0.119              1.38 (0.41,4.04)    0.584              2.63 (1.78,3.90)   1.38 × 10^− 6^     0.196            
  rs6003982           0.65 (0.37,1.17)    0.145              0.47 (0.27,0.80)                      4.98 × 103                               0.39 (0.23,0.65)                         2.48 × 10^− 4^     0.61 (0.30,1.18)    0.144              0.50 (0.38,0.67)   2.74 × 10^− 6^     0.557            
  rs4997823           0.40 (0.22,0.74)    1.89 × 10^− 3^     0.35 (0.19,0.64)                      4.02 × 10^− 4^                           0.72 (0.44,1.15)                         0.170              0.46 (0.20,0.98)    0.044              0.50 (0.37,0.67)   3.74 × 10^− 6^     0.279            
  rs7356945           2.52 (1.57,4.04)    1.21 × 10^− 4^     1.60 (1.06,2.43)                      0.026                                    1.26 (0.84,1.89)                         0.258              2.37 (1.25,4.63)    8.03 × 10^− 3^     1.74 (1.38,2.19)   2.77 × 10^− 6^     0.122            
  Decreased stream    rs7720298           2.20 (1.25,3.88)   7.45 × 10^− 3^                        3.38 (1.00,11.37)                        0.058[d](#tf0210){ref-type="table-fn"}   3.10 (1.96,4.90)   9.29 × 10^− 7^      NA                 NA                 2.75 (1.96,3.88)   6.52 × 10^− 9^   0.618
  rs17362923          3.58 (1.97,6.51)    3.28 × 10^− 5^     NA                                    NA                                       1.96 (1.20,3.20)                         7.75 × 10^− 3^     NA                  NA                 2.50 (1.71,3.65)   2.15 × 10^− 6^     0.126            
  rs76273496          3.96 (1.83,8.59)    1.31 × 10^− 3^     3.25 (0.65,16.14)                     0.191[d](#tf0210){ref-type="table-fn"}   2.94 (1.37,6.32)                         7.72 × 10^− 3^     NA                  NA                 3.39 (2.02,5.68)   3.45 × 10^− 6^     0.865            
  rs2203205           1.71 (1.16,2.54)    8.72 × 10^− 3^     2.28 (0.94,5.53)                      0.063[d](#tf0210){ref-type="table-fn"}   1.63 (1.22,2.19)                         1.13 × 10^− 3^     NA                  NA                 1.69 (1.35,2.13)   5.35 × 10^− 6^     0.785            
  rs141342719         5.11 (2.33,11.21)   7.29 × 10^− 5^     1.32 (0.22,7.88)                      0.762[d](#tf0210){ref-type="table-fn"}   2.58 (1.22,5.45)                         0.015              NA                  NA                 3.28 (1.96,5.52)   6.96 × 10^− 6^     0.270            
  rs673783            2.83 (1.50,5.34)    1.26 × 10^− 3^     2.14 (0.66,6.93)                      0.210[d](#tf0210){ref-type="table-fn"}   2.32 (1.38,3.89)                         1.52 × 10^− 3^     NA                  NA                 2.47 (1.69,3.61)   3.36 × 10^− 6^     0.865            
  rs62091368          5.93 (2.14,16.41)   1.62 × 10^− 3^     6.85 (1.70,27.60)                     0.016[d](#tf0210){ref-type="table-fn"}   2.81 (1.17,6.73)                         0.024              NA                  NA                 4.29 (2.36,7.80)   1.89 × 10^− 6^     0.422            
  rs144596911         4.41 (2.10,9.24)    2.24 × 10^− 4^     1.07 (0.10,12.00)                     0.954[d](#tf0210){ref-type="table-fn"}   3.44 (1.56,7.59)                         2.60 × 10^− 3^     NA                  NA                 3.69 (2.18,6.25)   1.20 × 10^− 6^     0.534            

OR, odds ratio.

CI, confidence interval.

NA, not available.

Adjusted for age and biologically effective dose (BED).

[^1]: Joint first authors.

[^2]: Joint last authors.
